We are live on ! Find out more
PVLA

Palvella Therapeutics

115 hedge funds and large institutions have $179M invested in Palvella Therapeutics in 2018 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 20 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more funds holding in top 10

Funds holding in top 10: 12 (+1)

50% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 30

0.02% more ownership

Funds ownership: 0.79%0.82% (+0.02%)

0% more funds holding

Funds holding: 115115 (0)

0% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 20

23% less capital invested

Capital invested by funds: $232M → $179M (-$53.7M)

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $486K

Holders
115
Holders Change
Holders Change %
0%
% of All Funds
2.63%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
20
Increased
45
Reduced
30
Closed
20
Calls
$1K
Puts
$486K
Net Calls
-$485K
Net Calls Change
+$244K
Name Holding Trade Value Shares
Change
Change in
Stake
Wellington Management Group
51
Wellington Management Group
Massachusetts
$450K
TA
52
Teachers Advisors
New York
$426K +$138K +290 +38%
AIM
53
Alambic Investment Management
California
$406K +$41.4K +87 +10%
California State Teachers Retirement System (CalSTRS)
54
California State Teachers Retirement System (CalSTRS)
California
$403K +$110K +231 +30%
Citadel Advisors
55
Citadel Advisors
Florida
$373K +$114K +239 +35%
Mariner
56
Mariner
Kansas
$330K
AIA
57
Affinity Investment Advisors
California
$308K
New York State Common Retirement Fund
58
New York State Common Retirement Fund
New York
$296K +$151K +317 +77%
RhumbLine Advisers
59
RhumbLine Advisers
Massachusetts
$241K +$85.7K +180 +44%
DS
60
DRW Securities
Illinois
$228K +$89.5K +188 +50%
AGM
61
Alpine Global Management
New York
$228K +$149K +313 +125%
Jacobs Levy Equity Management
62
Jacobs Levy Equity Management
New Jersey
$215K +$253K +531 New
Manulife (Manufacturers Life Insurance)
63
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$214K +$67.1K +141 +37%
Invesco
64
Invesco
Georgia
$199K -$474K -996 -67%
California Public Employees Retirement System
65
California Public Employees Retirement System
California
$179K +$210K +441 New
PCM
66
Piermont Capital Management
Missouri
$178K +$209K +439 New
AIG
67
American International Group
New York
$171K +$49K +103 +32%
Principal Financial Group
68
Principal Financial Group
Iowa
$164K +$102K +214 +112%
RJA
69
Raymond James & Associates
Florida
$162K -$6.66K -14 -3%
CSS
70
Cubist Systematic Strategies
Connecticut
$160K -$59K -124 -24%
BPM
71
Bowling Portfolio Management
Ohio
$156K +$183K +385 New
Squarepoint
72
Squarepoint
New York
$143K +$60K +126 +55%
State of Wisconsin Investment Board
73
State of Wisconsin Investment Board
Wisconsin
$132K
FRM
74
Fox Run Management
Connecticut
$124K +$146K +306 New
Two Sigma Investments
75
Two Sigma Investments
New York
$121K +$142K +298 New

PVLA Hedge Fund Activity: Q2 2018 in Review

115 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2018, worth a combined $179M — down 23% from $232M a quarter earlier.

Fund positioning in PVLA was balanced in Q2 2018: 20 funds opened new positions, 20 closed out, 45 added to existing stakes and 30 trimmed.

The largest buyer was BVF Inc, adding an estimated $10.4M. The largest seller was OrbiMed, cutting an estimated $14.3M.

  • 115 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2018, unchanged from Q1 2018.
  • Funds reported $179M of Palvella Therapeutics stock for Q2 2018, down 23% quarter-over-quarter.
  • 20 funds opened new Palvella Therapeutics positions in Q2 2018 and 20 closed out, a net change of 0 holders.
  • The largest Palvella Therapeutics buyer in Q2 2018 was BVF Inc, an estimated $10.4M added.
  • The largest Palvella Therapeutics seller in Q2 2018 was OrbiMed, an estimated $14.3M sold.

Based on aggregated 13F filings for Q2 2018.